View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2018	Oct. 25, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Document period end date	Sep. 30, 2018
Amendment flag	false
Document Period Focus	Q3
Document Fiscal Year Focus	2018
Current fiscal year end date	--12-31
Entity central index key	0001123494
Entity current reporting status	Yes
Entity filer category	Accelerated Filer
Entity registrant name	HARVARD BIOSCIENCE INC
Entity voluntary filers	No
Entity well known seasoned issuer	No
Entity common stock shares outstanding		37,293,918
Trading Symbol	HBIO

Statements of Financial Position - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 6,661	$ 5,192	$ 5,596
Accounts receivable, net of allowance for doubtful accounts of $301 and $193 respectively	17,880	13,382
Inventories	25,739	16,848
Other receivables and other assets	4,248	3,709
Current assets held for sale	0	8,404
Total current assets	54,528	47,535
Property, plant and equipment, net	5,392	3,743
Deferred income tax assets	179	182
Amortizable intangible assets, net	46,110	10,030
Goodwill	55,801	36,336
Other indefinite lived intangible assets	1,238	1,244
Other assets	1,792	324
Long term assets held for sale	0	9,960
Total Assets	165,040	109,354
Current liabilities:
Current portion, long-term debt	1,799	2,765
Accounts payable	5,392	4,410
Deferred revenue	3,267	505
Accrued income taxes	576	395
Accrued expenses	6,301	3,816
Other liabilities - current	1,926	293
Current liabilities held for sale	0	1,857
Total current liabilities	19,261	14,041
Long-term debt, less current installments	59,247	8,983
Deferred income tax liabilities	2,122	2,653
Other long term liabilities	3,451	1,466
Long term liabilities held for sale	0	1,311
Total liabilities	84,081	28,454
Commitments and contingencies
Stockholders Equity Abstract
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized	0	0
Common stock, par value $0.01 per share, 80,000,000 shares authorized; 45,032,925 and 42,763,985 shares issued and 37,287,418 and 35,018,478 shares outstanding, respectively	435	419
Additional paid-in-capital	225,530	218,792
Accumulated deficit	(122,751)	(116,967)
Accumulated other comprehensive loss	(11,587)	(10,676)
Treasury stock at cost, 7,745,507 common shares	(10,668)	(10,668)
Total stockholders' equity	80,959	80,900
Total liabilities and stockholders' equity	$ 165,040	$ 109,354

Statements of Financial Position (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
CONSOLIDATED BALANCE SHEETS
Allowance for doubtful accounts	$ 301	$ 193
Preferred Stock Par value	$ 0.01	$ 0.01
Preferred Stock - Shares Authorized	5,000,000	5,000,000
Common stock par value	$ 0.01	$ 0.01
Common Stock- Shares Authorized	80,000,000	80,000,000
Common Stock- Shares Issued	45,032,925	42,763,985
Common Stock- Shares Outstanding	37,287,418	35,018,478
Treasury Stock common shares	7,745,507	7,745,507

Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Statements of Operations - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 28,635	$ 18,717	$ 86,916	$ 55,761
Cost of revenues	12,818	9,217	42,475	27,611
Gross profit	15,817	9,500	44,441	28,150
Sales and marketing expenses	6,021	3,635	17,976	10,663
General and administrative expenses	4,655	4,317	15,297	13,219
Research and development expenses	2,783	1,538	7,943	4,119
Amortization of intangible assets	1,468	400	3,983	1,158
Total operating expenses	14,927	9,890	45,199	29,159
Operating loss	890	(390)	(758)	(1,009)
Other income (expense):
Foreign exchange	(26)	(73)	(28)	(488)
Interest expense, net	(1,458)	(189)	(3,835)	(532)
Other expense, net	(314)	(12)	(3,399)	(117)
Other expense, net	(1,798)	(274)	(7,262)	(1,137)
Loss from continuing operations before income taxes	(908)	(664)	(8,020)	(2,146)
Income tax expense (benefit)	(652)	(19)	(416)	(141)
Loss from continuing operations	(256)	(645)	(7,604)	(2,005)
Discontinued operations:
Income (loss) from discontinued operations before income taxes	0	254	937	231
Income tax (benefit) expense	0	26	(883)	90
Income (loss) from discontinued operations	0	228	1,820	141
Net loss	$ (256)	$ (417)	$ (5,784)	$ (1,864)
Loss per share:
Basic earnings per common share from continuing operations	$ (0.01)	$ (0.02)	$ (0.21)	$ (0.06)
Basic earnings (loss) per common share from discontinued operations	0	0.01	0.05	0
Basic loss per common share	(0.01)	(0.01)	(0.16)	(0.05)
Diluted loss per common share from continuing operations	(0.01)	(0.02)	(0.21)	(0.06)
Diluted earnings (loss) per common share from discontinued operations	0	0.01	0.05	0
Diluted loss per common share	$ (0.01)	$ (0.01)	$ (0.16)	$ (0.05)
Weighted average common shares:
Basic	36,947,052	34,840,324	36,169,536	34,705,947
Diluted	36,947,052	34,840,324	36,169,536	34,705,947
Comprehensive loss:
Net loss	$ (256)	$ (417)	$ (5,784)	$ (1,864)
Foreign currency translation adjustments	395	1,181	(1,037)	4,189
Derivatives qualifying as hedges, net of tax:
(Loss) gain on derivative instruments designated and qualifying as cash flow hedges	126	0	27	(89)
Amounts reclassified from accumulated other comprehensive loss to net loss	55	21	99	43
Total comprehensive loss	$ 320	$ 785	$ (6,695)	$ 2,279

Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (5,784)	$ (1,864)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	2,232	2,604
Depreciation	1,474	1,009
Gain on sale of Denville	(1,251)	0
Loss on disposal of fixed assets	(3)	0
Amortization Of Catalog Costs	20	31
Provision for allowance for doubtful accounts	3	1
Amortization of Intangible Assets	4,030	1,825
Amortization of deferred financing costs	511	36
Deferrred Income Taxes	49	0
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	918	1,000
Decrease in inventories	2,112	(608)
Decrease (increase) in other receivables and other assets	(1,184)	(563)
Increase (decrease) in trade accounts payable	(442)	(786)
Decrease in accrued income taxes	211	35
Decrease in accrued expenses	(1,968)	(830)
Increase in deferred revenue	1,929	99
(Decrease) increase in other liabilities	(2,566)	7
Net cash provided by operating activities	291	1,996
Cash flows used in investing activities:
Additions to property, plant and equipment	(891)	(677)
Additions to catalog costs	(24)	(39)
Acquisitions, net of cash acquired	(68,008)	0
Disposition, net of cash sold	15,754	0
Net cash used in investing activities	(53,169)	(716)
Cash flows provided by (used in) financing activities:
Proceeds from issuance of debt	70,800	2,250
Repayments of debt	(19,947)	(3,502)
Payments of debt issuance costs	(1,967)	0
Net proceeds from (net taxes paid for) issuance of common stock	4,521	(101)
Net cash provided by (used in) financing activities	53,407	(1,353)
Effect of exchange rate changes on cash	399	313
Increase in cash and cash equivalents	928	240
Cash and cash equivalents at the beginning of period, including cash included in assets held for sale	5,733	5,596
Cash and cash equivalents at the end of period	6,661	5,836
Supplemental disclosures of cash flow information [Abstract]
Cash paid for interest	3,509	503
Cash refunded for income taxes	$ (170)	$ (96)

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies Disclosure [Text Block]	HARVARD BIOSCIENCE, INC. NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of September 30, 2018 and for the nine months ended September 30, 2018 and 2017 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2017 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 16, 2018. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2018, results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future periods. Reclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that has and will have a major effect on the Company’s operations and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and nine months ended September 30, 2018 and 2017 have been presented in discontinued operations in the consolidated statements of operations. Additionally, the assets and liabilities of Denville as of December 31, 2017 have been recast in the consolidated balance sheet and presented as held for sale. These reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive income (loss), consolidated statements of cash flows for any of the periods presented. Summary of Significant Accounting Policies The accounting policies underlying the accompanying unaudited consolidated financial statements are those set forth in Note 2 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on March 16, 2018. Except for the accounting for revenue arising from contracts with customers as noted below there have been no material changes in the company’s significant accounting policies during the nine months ended September 30, 2018. Revenue recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at universities, hospitals, government laboratories, including the United States National Institute of Health (NIH), contract research organizations, pharmaceutical and biotechnology companies. The Company also has global and regional distribution partners, and original equipment manufacturer (OEM) customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program”. Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right based on the applicable guidance within ASC 606. Service revenues consist of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not a separate performance obligation. Extended warranties relate to warranties that are separately priced, and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from service, maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, based on time elapsed, which is generally on a straight-line basis over the service period. The period over which maintenance and warranty contracts is recognized is typically one year. The period over which service revenues is recognized is generally less than one month. For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to any and all remaining performance obligations are generally expected to be recognized in one year or less, as the majority of the Company's contracts have a term of less than one year. Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration, and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented. The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which generally occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of its customers and the products or services offered. Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis, and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one year. The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products that they have made a prepayment for. Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not acquired prior to the termination of the contract period. Allowance for doubtful accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence. Disaggregation of revenue Refer to Note 17 for revenue disaggregated by type and by geographic region as well as further information about the allowance for doubtful accounts and deferred revenue balances.

Recently Issued Accounting Pronouncements	9 Months Ended
Recently Issued Accounting Pronouncements	Sep. 30, 2018
Recently Issued Accounting Pronouncements [Abstract]
Recently Issued Accounting Pronouncements Disclosure [Text Block]	2. Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-02, Leases, which is intended to improve financial reporting about leasing transactions. The update requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by lease terms of more than 12 months. The update is effective for fiscal years beginning after December 15, 2018. A modified retrospective transition approach is required for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company expects to utilize a practical expedient in its method of adoption of the standard. Under this expedient, which is a “current-period adjustment method,” the Company would apply ASC 842 as of January 2019 and record a cumulative-effect adjustment to retained earnings as of that date. The Company has collected information on its leases and is in the process of evaluating and applying the requirements of the standard to its leases. The Company has not yet concluded on the impact of the adoption on its consolidated financial position, results of operations and cash flows; however, the Company expects that the new standard will have a material effect on its consolidated balance sheet related to the recognition of new assets and lease liabilities. The Company expects to finalize its classification of leases as well as the effective interest rate to be applied in determining the lease liabilities during the fourth quarter of 2018. The Company’s future commitments under lease obligations are summarized in Note 12. In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815) which amends the hedge accounting recognition and presentation requirements in ASC 815, Derivatives and Hedging. The Board’s objectives in issuing the ASU are to (1) improve the transparency and understandability of information conveyed to financial statement users about an entity’s risk management activities by better aligning the entity’s financial reporting for hedging relationships with those risk management activities and (2) reduce the complexity of and simplify the application of hedge accounting by preparers. The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period. The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, a new accounting standard that provides for a comprehensive model to use in the accounting for revenue arising from contracts with customers that will replace most existing revenue recognition guidance within generally accepted accounting principles in the United States. Under this standard, revenue will be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company adopted this standard as of January 1, 2018 using the modified retrospective approach, and applied the guidance to contracts that were not completed at the date of adoption. The Company’s significant revenue streams currently consist primarily of product revenue transactions, service, maintenance and extended warranty transactions on certain product sales. The timing of recognizing revenues for these revenue streams did not materially change. Additionally, the adoption of ASU 2014-09 did not have a material impact on the Company’s financial position, results of operations, equity or cash flows as of the adoption date or for the three months ended March 31, 2018. The Company’s updated revenue recognition policy is described in Note 1 and disaggregated revenue disclosures required under ASC 2014-09 are presented in Note 17. In May 2017, the FASB issued ASU 2017-09, Stock compensation (Topic 718): Scope of modification accounting which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. Specifically, an entity would not apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The ASU is effective for annual reporting periods, including interim periods within those annual reporting periods, beginning after December 15, 2017. The Company adopted this guidance on January 1, 2018, and the new standard did not have a material impact on its consolidated financial position, results of operations and cash flows.

Accumulated Other Comprehensive Income

9 Months Ended

Sep. 30, 2018

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income Disclosure [Text Block]

3. Accumulated Other Comprehensive Loss

Changes in each component of accumulated other comprehensive loss, net of tax are as follows:

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2017	$	(9,755)	$	37	$	(958)	$	(10,676)

Other comprehensive income before reclassifications		(1,037)		27		-		(1,010)
Amounts reclassified from AOCI		-		99		-		99

Other comprehensive income		(1,037)		126		-		(911)

Balance at September 30, 2018	$	(10,792)	$	163	$	(958)	$	(11,587)

Acquisitions

9 Months Ended

Sep. 30, 2018

Acquisition Disclosure [Abstract]

Acquisitions Disclosure [Text Block]

4. Acquisition

On January 31, 2018, the Company acquired all of the issued and outstanding shares of Data Sciences International, Inc. (DSI), a Delaware corporation, for approximately $70.6 million. The Company funded the acquisition from its existing cash balances, excess proceeds from the Denville Transaction discussed in Note 5, and proceeds from the Financing Agreement discussed in Note 14.

DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers. Its customers include pharmaceutical and biotechnology companies, as well as contract research organizations, academic labs and government researchers. This acquisition diversifies the Company’s customer base into the biopharmaceutical and contract research organization markets.

The aggregate purchase price for this acquisition was preliminarily allocated to tangible and intangible net assets acquired as follows:

		(in thousands)
Tangible assets	$	32,525
Liabilities assumed		(11,587)
Net assets		20,938

Goodwill and intangible assets:
Goodwill		19,348
Amortizable intangible assets:
Trade name		3,524
Developed technology		25,570
Customer relationships		9,837
In-process research and development		1,387
Total amortizable intangible assets		40,318
Deferred tax liabilities, net		(10,020)
Total goodwill and intangible assets, net of tax		49,646
Acquisition purchase price	$	70,584


Tangible assets and liabilities assumed, as referenced above, preliminarily consist of the following:

Cash acquired	$	2,576
Accounts receivable, net		5,069
Inventories		11,512
Other current assets		809
Property, plant and equipment, net		2,090
Deferred income tax assets, net		10,469
Tangible assets	$	32,525

Accounts payable and accrued liabilities	$	5,639
Deferred revenue including customer advances		2,976
Other long term liabilities		2,972
Liabilities assumed	$	11,587

The preliminary allocation of the purchase price for DSI was based on estimates of the fair value of the net assets acquired and is subject to adjustment upon finalization of the valuation of the acquired intangible assets and the related deferred taxes. Measurements of these items inherently require significant estimates and assumptions. During the three months ended June 30, 2018, the Company made adjustments to the preliminary allocation of the purchase price presented in the March 31, 2018 Form 10-Q. The adjustments included a decrease of $1.6 million to other long term liabilities, an increase of $1.4 million to deferred tax liabilities, an increase of $0.6 million to the purchase price related to a net working capital adjustment, and an increase of $0.6 million to goodwill.

The weighted-average amortization periods for definite-lived intangible assets acquired are 9.4 years for tradenames, 8.2 years for developed technology, 12.4 years for customer relationships and 7.4 years for in-process research and development assets. The weighted average amortization period for all definite-lived intangible assets acquired is 9.3 years.

Goodwill recorded as a result of the acquisition of DSI is not deductible for tax purposes.

The results of operations for DSI have been included in the Company’s consolidated financial statements from the date of acquisition. The revenues of DSI included in the Company’s consolidated statement of operations from the date of acquisition were approximately $29.3 million for the eight-month period ended September 30, 2018. The net loss of DSI included in the Company’s consolidated statement of operations for the same period was approximately $31 thousand. Included in the net loss was a $3.8 million charge recognized in cost of revenues related to purchase accounting inventory fair value step up amortization. The total inventory fair value step up was preliminarily valued at $3.8 million and was recognized into cost of revenues over one inventory turn, or approximately five and a half months. Also included in the net loss of DSI is $2.9 million of intangible asset amortization expense.

The following consolidated pro forma information is based on the assumption that the acquisition of DSI occurred on January 1, 2017. Accordingly, the historical results have been adjusted to reflect amortization expense, interest expense and other purchase accounting adjustments that would have been recognized on such a pro forma basis. The pro forma information is presented for comparative purposes only and is not necessarily indicative of the financial position or results of operations which would have been reported had the Company completed the acquisition during these periods or which might be reported in the future.

		Three Months Ended September 30,				Nine Months Ended September 30,
		Three Months Ended September 30,				Nine Months Ended September 30,
		2018		2017		2018		2017
		(in thousands)
Pro Forma
Revenues	$	28,713	$	27,997	$	90,384	$	88,547
Income (loss) from continuing operations		155		(1,845)		(236)		(9,719)

Direct acquisition costs recorded in other expense, net in the Company’s consolidated statements of operations were $3.0 million and $0 for the nine months ended September 30, 2018 and 2017, respectively.

Discontinued Operations

9 Months Ended

Sep. 30, 2018

Discontinued Operations [Abstract]

Discontinued Operations Disclosure [Text Block]

5. Discontinued Operations

On January 22, 2018, the Company sold substantially all the assets of its wholly owned subsidiary, Denville, for approximately $20.0 million, which includes a $3.0 million earn-out provision (the Denville Transaction). Upon the closing of the transaction, the Company received $15.7 million. The $3.0 million earn-out provision represents consideration that is contingent on Denville achieving certain performance metrics over a period of two years.

The following table is a reconciliation of the carrying amounts of major assets and liabilities of Denville classified as held for sale in the Company’s consolidated balance sheet as of December 31, 2017.


			December 31,
			2017
		(in thousands)
Carrying amounts of major classes of assets
	Cash	$	541
	Accounts receivable, net		2,854
	Inventories		4,505
	Other receivables and other assets		504
	Current assets held for sale		8,404

	Property, plant and equipment		397
	Amortizable intangible assets		5,930
	Allocation of goodwill		3,633
	Long term assets held for sale		9,960
Total assets of the disposal group classified as held for sale in the consolidated balance sheet		$	18,364

Carrying amounts of major classes of liabilities
	Accounts payable and accrued expenses	$	1,736
	Other current liabilities		121
	Current liabilities held for sale		1,857

	Deferred income tax liabilities		1,311
	Long term liabilities held for sale		1,311
Total liabilities of the disposal group classified as held for sale in the consolidated balance sheet		$	3,168

The following table is a reconciliation of the major line items of income from discontinued operations presented within the Company’s consolidated statements of operations for the three and nine months ended September 30, 2018 and 2017.

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018			2017	2018			2017
	(in thousands)				(in thousands)
Revenues	$	-	$	6,333	$	893	$	18,658
Cost of revenues		-		(4,194)		(534)		(12,383)
Operating and other expenses		-		(1,885)		(673)		(6,044)
Gain on disposal of discontinued operations		-		-		1,251		-
Income from discontinued operations before income taxes	$	-	$	254	$	937	$	231
Income tax expense (benefit)		-		26		(883)		90
Income from discontinued operations		-		228		1,820		141

Included within the adjustments to reconcile net loss to net cash provided by operating activities in the Company’s consolidated statements of cash flows for the nine months ended September 30, 2018 and 2017, was amortization of intangible assets for Denville of $47 thousand and $0.7 million, respectively. Depreciation and capital expenditures for Denville were immaterial for both periods presented.

Goodwill and Other Intangible Assets

9 Months Ended

Sep. 30, 2018

Goodwill And Other Intangible Assets Disclosure [Abstract]

Goodwill And Other Intangible Assets Disclosure [Text Block]

6. Goodwill and Other Intangible Assets

Intangible assets consist of the following:

									Weighted
									Average
		September 30, 2018				December 31, 2017			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	41,536	$	(15,516)	$	16,173	$	(13,179)	7.3	Years
Trade names		7,882		(2,718)		4,443		(2,280)	7.9	Years
Distribution agreements/customer relationships		22,808		(9,240)		13,197		(8,373)	10.8	Years
In-process research and development		1,387		(47)		-		-	7.2	Years
Patents		218		(200)		223		(174)	0.4	Years
Total amortizable intangible assets		73,831	$	(27,721)		34,036	$	(24,006)

Indefinite-lived intangible assets:
Goodwill		55,801				36,336
Other indefinite-lived intangible assets		1,238				1,244
Total goodwill and other indefinite-lived intangible assets		57,039				37,580

Total intangible assets, gross	$	130,870			$	71,616

(a) Weighted average life as of September 30, 2018.

The balances presented in the tables above and below exclude intangible assets and allocated goodwill of Denville as of December 31, 2017. Both balances are reported as long term assets held for sale as of December 31, 2017. Refer to Note 5 for further details.

The change in the carrying amount of goodwill for the nine months ended September 30, 2018 is as follows:

			(in thousands)
Balance at December 31, 2017		$	36,336
	Goodwill arising from business combination		19,348
	Effect of change in currency translation		117
Balance at September 30, 2018		$	55,801

Amortization of intangible assets

Intangible asset amortization expense from continuing operations was $1.5 million and $0.4 million for the three months ended September 30, 2018 and 2017, respectively. Intangible asset amortization expense from continuing operations was $4.0 million and $1.2 million for the nine months ended September 30, 2018 and 2017, respectively. Amortization expense of existing amortizable intangible assets is currently estimated to be $5.6 million for the year ending December 31, 2018, $5.8 million for the year ending December 31, 2019, $5.8 million for the year ending December 31, 2020, $5.7 million for the year ending December 31, 2021 and $5.7 million for the year ending December 31, 2022.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Inventories

9 Months Ended

Sep. 30, 2018

Inventories Disclosure [Abstract]

Inventories Disclosure [Text Block]

7. Inventories

Inventories consist of the following:

			September 30,		December 31,
			2018		2017
			(in thousands)
Finished goods		$	7,569	$	5,779
Work in process			3,849		1,042
Raw materials			14,321		10,027
	Total	$	25,739	$	16,848

Property, Plant and Equipment

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment Disclosure [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

8. Property, Plant and Equipment

As of September 30, 2018 and December 31, 2017, property, plant and equipment consist of the following:

		September 30,		December 31,
		2018		2017
		(in thousands)
Land, buildings and leasehold improvements	$	2,478	$	2,197
Machinery and equipment		8,711		7,022
Computer equipment and software		9,519		8,819
Furniture and fixtures		1,789		1,139
Automobiles		117		120
		22,614		19,297
Less: accumulated depreciation		(17,222)		(15,554)
Property, plant and equipment, net	$	5,392	$	3,743

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	9. Related Party Transactions As part of the acquisitions of Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI) in 2014, the Company signed lease agreements with the former owners of the acquired companies. The principals of such former owners of MCS and TBSI were employees of the Company as of September 30, 2018 and 2017. Pursuant to a lease agreement, the Company made rent payments of approximately $77 thousand and $64 thousand to the former owners of MCS for the three months ended September 30, 2018 and 2017, respectively. The Company made rent payments of approximately $10 thousand to the former owner of TBSI for both the three months ended September 30, 2018 and 2017. The Company made rent payments of approximately $0.2 million to the former owners of MCS for both the nine months ended September 30, 2018 and 2017. The Company made rent payments of approximately $32 thousand to the former owner of TBSI for both the nine months ended September 30, 2018 and 2017.

Warranties

9 Months Ended

Sep. 30, 2018

Warranties Disclosure [Abstract]

Warranties Disclosure [Text Block]

10. Warranties

Warranties are estimated and accrued at the time revenues are recorded. A rollforward of the Company’s product warranty accrual is as follows:

		Beginning	(Payments)\			Ending
		Balance	Credits	Additions		Balance
		(in thousands)

Year ended December 31, 2017	$	193	(7)	60	$	246

Nine months ended September 30, 2018	$	246	5	140	$	391

Employee Benefit Plans

9 Months Ended

Sep. 30, 2018

Employee Benefit Plans Disclosure [Abstract]

Employee Benefit Plans Disclosure [Text Block]

11. Employee Benefit Plans

The Company’s subsidiary in the United Kingdom, Biochrom Limited, maintains contributory, defined benefit pension plans for substantially all of its employees. These defined benefit pension plans have been closed to new employees since 2014, as well as closed to the future accrual of benefits for existing employees. The components of the Company’s defined benefit pension expense were as follows:

		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2018		2017		2018		2017
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	121	$	141	$	371	$	399
Expected return on plan assets		(187)		(179)		(575)		(505)
Net amortization loss		53		98		163		276
Curtailment gain		(41)		-		(41)		-
Net periodic benefit (income) cost	$	(54)	$	60	$	(82)	$	170

For the three months ended September 30, 2018 and 2017, the Company contributed $0.2 million, for both periods, to its defined benefit pension plans. For the nine months ended September 30, 2018 and 2017, the Company contributed $0.5 million for both periods, to its defined benefit pension plans. The Company expects to contribute approximately $0.2 million to its defined benefit pension plans during the remainder of 2018.

The Company had an underfunded pension liability of approximately $1.2 million as of September 30, 2018 and December 31, 2017, respectively, included in the other long term liabilities line item in the consolidated balance sheets.

Leases

9 Months Ended

Sep. 30, 2018

Leases Disclosure [Abstract]

Leases Disclosure [Text Block]

12. Leases

The Company has noncancelable operating leases for office and warehouse space expiring at various dates through 2023 and thereafter. Rent payments are estimated to be $3.4 million for the year ended December 31, 2018. Rent payments for continuing operations were approximately $0.9 million and $0.5 million for the three months ended September 30, 2018 and 2017, respectively. Rent payments for continuing operations were approximately $2.6 million and $1.3 million for the nine months ended September 30, 2018 and 2017, respectively.

Future minimum lease payments for operating leases, with initial or remaining terms in excess of one year at September 30, 2018, are as follows:

		Operating
		Leases
		(in thousands)
2019	$	3,217
2020		2,317
2021		1,130
2022		1,091
2023		1,093
Thereafter		772
Net minimum lease payments	$	9,620

Capital Stock

9 Months Ended

Sep. 30, 2018

Capital Stock Disclosure [Abstract]

Capital Stock Disclosure [Text Block]

13. Capital Stock

Common Stock

On February 5, 2008, the Company’s Board of Directors adopted a Shareholder Rights Plan and declared a dividend distribution of one preferred stock purchase right for each outstanding share of the Company’s common stock to shareholders of record as of the close of business on February 6, 2008. These rights were not initially exercisable and would trade with the shares of the Company’s common stock. The rights would become exercisable under various conditions according to the terms of the plan. The Shareholder Rights Plan expired, with no rights having become exercisable, in accordance with its terms on the close of business on February 6, 2018.

Preferred Stock

The Company’s Board of Directors has the authority to issue up to 5.0 million shares of preferred stock and to determine the price privileges and other terms of the shares. The Board of Directors may exercise this authority without any further approval of stockholders. As of September 30, 2018, the Company had no preferred stock issued or outstanding.

Employee Stock Purchase Plan (as amended, the ESPP)

In 2000, the Company approved the ESPP. Under this ESPP, participating employees can authorize the Company to withhold a portion of their base pay during consecutive six-month payment periods for the purchase of shares of the Company’s common stock. At the conclusion of the period, participating employees can purchase shares of the Company’s common stock at 85% of the lower of the fair market value of the Company’s common stock at the beginning or end of the period. Shares are issued under the ESPP for the six-month periods ending June 30 and December 31. On May 18, 2017, the stockholders of the Company approved an increase of 300,000 shares of common stock in the number of shares available for issuance under the ESPP. Following such amendment, 1,050,000 shares of common stock are authorized for issuance, of which 826,361 shares were issued as of September 30, 2018. There were 24,907 and 36,902 shares issued under the ESPP during the nine months ended September 30, 2018 and 2017, respectively.

Stock Option and Equity Incentive Plans

Third Amended and Restated 2000 Stock Option and Incentive Plan (as amended, the Third A&R Plan)

The Third Amendment to the Third A&R Plan (the Amendment) was adopted by the Board of Directors on April 2, 2018. Such Amendment was approved by the stockholders at the Company’s 2018 Annual Meeting of Stockholders. Pursuant to the Amendment, the aggregate number of shares authorized for issuance under the Third A&R Plan was increased by 3,400,000 shares to 20,908,929.

Restricted Stock Units with a Market Condition (the Market Condition RSUs)

On August 3, 2015, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2015 Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan. The vesting of these 2015 Market Condition RSUs was cliff-based and linked to the achievement of a relative total shareholder return of the Company’s common stock from August 3, 2015 to the earlier of (i) August 3, 2018 or (ii) upon a change of control (measured relative to the Russell 3000 index and based on the 20-day trading average price before each such date). As of August 3, 2018, certain of the target total shareholder returns were achieved, and as a result, 69,667 of the 2015 Market Condition RSUs vested. The remaining 2015 Market Condition RSUs did not vest and were canceled.

On May 24, 2018, the Compensation Committee of the Board of Directors of the Company approved and granted deferred stock awards of Market Condition RSUs (the 2018 Market Condition RSUs) to certain members of the Company’s management team under the Third A&R Plan. The vesting of the 2018 Market Condition RSUs is based on a graded-vesting schedule (one third at the end of each year for three years) and linked to the achievement of a relative total shareholder return of the Company’s common stock from May 24, 2018 to the earlier of (i) May 24, 2019 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). As of September 30, 2018, the target number of these restricted stock units that may be earned is 116,944 shares; the maximum amount is 150% of the target number.

Stock-Based Payment Awards

The Company accounts for stock-based payment awards in accordance with the provisions of FASB ASC 718, which requires it to recognize compensation expense for all stock-based payment awards made to employees and directors including stock options, restricted stock units, Market Condition RSUs and employee stock purchases related to the ESPP.

The Company adopted ASU 2016-09 as of January 1, 2017. As a result of this adoption, the Company has elected as an accounting policy to account for forfeitures for service based awards as they occur, with no adjustment for estimated forfeitures. The Company recognized as of January 1, 2017, a cumulative effect adjustment of $0.1 million to reduce retained earnings as required under the modified retrospective approach.

Stock option and restricted stock unit activity under the Company’s Third A&R Plan for the nine months ended September 30, 2018 was as follows:

		Stock Options			Restricted Stock Units			Market Condition RSU's
				Weighted
		Stock		Average	Restricted			Market
		Options		Exercise	Stock Units		Grant Date	Condition RSU's		Grant Date
		Outstanding		Price	Outstanding		Fair Value	Outstanding		Fair Value

Balance at December 31, 2017		3,780,244	$	3.95	1,796,927	$	2.69	164,127	$	4.81
	Granted	50,000		4.84	608,189		4.34	156,944		4.19
	Exercised	(1,689,755)		3.50	-		-	-		-
	Vested (RSUs)	-		-	(824,843)		2.87	(69,667)		4.81
	Cancelled / forfeited	(204,391)		4.96	(346,462)		2.82	(134,460)		4.63
Balance at September 30, 2018		1,936,098	$	4.26	1,233,811	$	3.35	116,944	$	4.19

The weighted average fair value of the options granted under the Third A&R Plan during the three months ended September 30, 2018 and 2017 was $2.34 and $1.24, respectively. The weighted average fair value of the options granted under the Third A&R Plan during the nine months ended September 30, 2018 and 2017 was $1.97 and $1.17, respectively. The following assumptions were used to estimate the fair value, using the Black-Scholes option pricing model, of stock options granted during the three and nine months ended September 30, 2018 and 2017:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Volatility	43.38	%	41.99	%	42.63	%	41.30	%
Risk-free interest rate	2.78	%	1.74	%	2.81	%	1.88	%
Expected holding period (in years)	4.77	years	5.10	years	4.90	years	5.16	years
Dividend yield	-	%	-	%	-	%	-	%

The weighted average fair value of the 2018 Market Condition RSUs which were granted under the Third A&R Plan during the nine months ended September 30, 2018 was $4.19. There were no Market Condition RSUs granted during the three and nine months ended September 30, 2017. The following assumptions were used to estimate the fair value, using a Monte-Carlo valuation simulation, of the Market Condition RSUs granted during the nine months ended September 30, 2018:

	Nine Months Ended
	September 30,
	2018
Volatility	44.02	%
Risk-free interest rate	2.27	%
Correlation coefficient	0.07	%
Dividend yield	-	%

The Company used historical volatility to calculate the expected volatility for each grant as of the grant date. Historical volatility was determined by calculating the mean reversion of the daily adjusted closing stock price. The risk-free interest rate assumption is based upon observed U.S. Treasury bill interest rates (risk-free) appropriate for the term of the Company’s stock options and Market Condition RSUs. The expected holding period of stock options represents the period of time options are expected to be outstanding and is based on historical experience. The vesting period ranges from one to four years and the contractual life is ten years. The correlation coefficient, used to value the Market Condition RSUs, represents the way in which entities move in relation to the NASDAQ Biotechnology index as a whole.

Stock-based compensation expense related to stock options, restricted stock units, Market Condition RSUs and the ESPP for the three and nine months ended September 30, 2018 and 2017 was allocated as follows:

		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2018		2017		2018		2017
		(in thousands)

Cost of revenues	$	19	$	16	$	45	$	45
Sales and marketing		105		150		331		395
General and administrative		308		706		1,581		1,989
Research and development		54		36		125		102
Discontinued operations		-		25		150		73
Total stock-based compensation	$	486	$	933	$	2,232	$	2,604

The Company did not capitalize any stock-based compensation.

Earnings per share

Basic earnings per share is based upon net income divided by the number of weighted average common shares outstanding during the period. The calculation of diluted earnings per share assumes conversion of stock options, restricted stock units and Market Condition RSUs into common stock using the treasury method. The weighted average number of shares used to compute basic and diluted earnings per share consists of the following:

	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2018	2017	2018	2017

Basic	36,947,052	34,840,324	36,169,536	34,705,947
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs	-	-	-	-
Diluted	36,947,052	34,840,324	36,169,536	34,705,947

Excluded from the shares used in calculating the diluted earnings per common share in the above table are options, restricted stock units and Market Condition RSUs of approximately 3,286,853 and 5,789,838 shares of common stock for the three and nine months ended September 30, 2018 and 2017, respectively, as the impact of these shares would be anti-dilutive.

Long Term Debt

9 Months Ended

Sep. 30, 2018

Long Term Debt Disclosure [Abstract]

Long Term Debt Disclosure [Text Block]

14. Long Term Debt

On January 22, 2018, in connection with the closing of the Denville Transaction, the Company terminated the Third Amended and Restated Credit Agreement (the Credit Agreement), among the Company, Brown Brothers Harriman & Co. and each of the other lenders party thereto, and Bank of America, as administrative agent. All outstanding amounts under the agreement were repaid in full using a portion of the proceeds of the Denville Transaction. At the time of repayment, there was approximately $11.9 million outstanding.

On January 31, 2018, the Company entered into a financing agreement by and among the Company and certain subsidiaries of the Company parties thereto, as borrowers (collectively, the Borrower), certain subsidiaries of the Company parties thereto, as guarantors, various lenders from time to time party thereto (the Lenders), and Cerberus Business Finance, LLC, as collateral agent and administrative agent for the Lenders (the Financing Agreement). On August 16, 2018, the Company and Cerberus Business Finance, LLC entered into a First Amendment to the Financing Agreement, which such amendment modified certain provisions related to the borrowing base and reporting, among other things.

The Financing Agreement provides for senior secured credit facilities (the Senior Secured Credit Facilities) comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. The proceeds of the term loan and $4.8 million of advances under the revolving line of credit were used to fund a portion of the DSI acquisition, and to pay fees and expenses related thereto and the closing of the Senior Secured Credit Facilities. In addition, the revolving facility is available for use by the Company and its subsidiaries for general corporate and working capital needs, and other purposes to the extent permitted by the Financing Agreement. The Senior Secured Credit Facilities have a maturity of five years.

Commencing on March 31, 2018, the outstanding term loans amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.

The obligations of the Borrower under the Senior Secured Credit Facilities are unconditionally guaranteed by the Company and certain of the Company’s existing and subsequently acquired or organized subsidiaries. The Senior Secured Credit Facilities and related guarantees are secured on a first-priority basis (subject to certain liens permitted under the Financing Agreement) by a lien on substantially all the tangible and intangible assets of the Borrower and the subsidiary guarantors, including all of the capital stock held by such obligors (subject to a 65% limitation on pledges of capital stock of foreign subsidiaries), subject to certain exceptions.

Interest on all loans under the Senior Secured Credit Facilities is paid monthly. Borrowings under the Financing Agreement accrue interest at a per annum rate equal to, at the Borrower’s option, a base rate plus 4.75% or a London Interbank Offered Rate (LIBOR) rate plus 6.25%. The loans are also subject to a 1.25% interest rate floor for LIBOR loans and a 4.25% interest rate floor for base rate loans.

The Financing Agreement contains customary representations and warranties and affirmative covenants applicable to the Company and its subsidiaries and also contains certain restrictive covenants, including, among others, limitations on the incurrence of additional debt, liens on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of the Company’s capital stock, prepayments of certain debt, transactions with affiliates and modifications of organizational documents, material contracts, affiliated practice agreements and certain debt agreements. The Financing Agreement also contains customary events of default. As of September 30, 2018, the Company was in compliance with all financial covenants contained in the Financing Agreement, was subject to covenant and working capital borrowing restrictions and had available borrowing capacity under its Financing Agreement of $8.5 million.

As of September 30, 2018 and December 31, 2017, the Company had borrowings net of debt issuance costs of $61.0 million and $11.7 million respectively, outstanding. The carrying value of the debt approximates fair value because the interest rate under the obligation approximates market rates of interest available to the Company for similar instruments.

As of September 30, 2018, the weighted effective interest rate, net of the impact of the Company’s interest rate swap, on its term loan was 8.76%.

As of September 30, 2018 and December 31, 2017, the Company’s borrowings were comprised of:

		September 30,		December 31,
		2018		2017
		(in thousands)
Long-term debt:
Term loan	$	62,752	$	11,899
Total unamortized deferred financing costs		(1,706)		(151)
Total debt		61,046		11,748
Less: current installments		(2,200)		(2,800)
Current unamortized deferred financing costs		401		35
Long-term debt	$	59,247	$	8,983

Derivatives

9 Months Ended

Sep. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

15. Derivatives

The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.

By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty and, therefore, the Company is not exposed to the counterparty’s credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with carefully selected major financial institutions based upon their credit profile.

Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.

The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company’s outstanding or forecasted debt obligations as well as the Company’s offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company’s future cash flows.

The Company uses variable-rate LIBOR debt to finance its operations. The debt obligations expose the Company to variability in interest payments due to changes in interest rates. Management believes that it is prudent to limit the variability of a portion of its interest payments. To meet this objective, management enters into LIBOR based interest rate swap agreements to manage fluctuations in cash flows resulting from changes in the benchmark interest rate of LIBOR. These swaps change the variable-rate cash flow exposure on the debt obligations to fixed cash flows. Under the terms of the interest rate swaps, the Company receives LIBOR based variable interest rate payments and makes fixed interest rate payments, thereby creating the equivalent of fixed-rate debt for the notional amount of its debt hedged.

As disclosed in Note 14, on January 31, 2018, the Company entered into a Financing Agreement comprised of a $64.0 million term loan and up to a $25.0 million revolving line of credit. Shortly after entering into this Credit Agreement, the Company entered into an interest rate swap contract with PNC Bank with a notional amount of $36.0 million and a termination date of January 1, 2023 in order to hedge the risk of changes in the effective benchmark interest rate (LIBOR) associated with the Company’s Term Loan. The swap contract converted specific variable-rate debt into fixed-rate debt and fixed the LIBOR rate associated with a portion of the term loan under the Financing Agreement at 2.72%. The interest rate swap was designated as a cash flow hedge instrument in accordance with ASC 815 “Derivatives and Hedging”.

The notional amount of the Company’s derivative instruments as of September 30, 2018 was $34.7 million.

The following table presents the notional amount and fair value of the Company’s derivative instruments as of September 30, 2018 and December 31, 2017.


				September 30, 2018		September 30, 2018
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	34,663	$	163


				December 31, 2017		December 31, 2017
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	11,900	$	37

	(a) See Note 16 for the fair value measurements related to these financial instruments.

All of the Company’s derivative instruments are designated as hedging instruments.

The Company has structured its interest rate swap agreements to be 100% effective and as a result, there was no impact to earnings resulting from hedge ineffectiveness. Changes in the fair value of interest rate swaps designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income (AOCI). These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings. The Company’s interest rate swap agreement was deemed to be fully effective in accordance with ASC 815, and, as such, unrealized gains and losses related to these derivatives were recorded as AOCI.

The following table summarizes the effect of derivatives designated as cash flow hedging instruments and their classification within comprehensive loss for the three and nine months ended September 30, 2018 and 2017:

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
	(in thousands)
Interest rate swaps	$	126	$	-	$	27	$	(89)

The following table summarizes the reclassifications out of accumulated other comprehensive loss for the nine months ended September 30, 2018 and 2017:

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)
	Three Months Ended September 30,				Nine Months Ended September 30,				Location of amount reclassified from AOCI
	2018		2017		2018		2017		into income (effective portion)
	(in thousands)
Interest rate swaps	$	55	$	21	$	99	$	43	Interest expense

As of September 30, 2018, $54 thousand of deferred losses on derivative instruments accumulated in AOCI are expected to be reclassified to earnings during the next twelve months. Transactions and events expected to occur over the next twelve months that will necessitate reclassifying these derivatives’ losses to earnings include the repricing of variable-rate debt. As a result of terminating the Credit Agreement, as discussed in Note 14, the Company unwound its previous May 2017 interest rate swap contract and received $0.1 million in proceeds.

Fair Value Measurements

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

16. Fair Value Measurements

Fair value measurement is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy is established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s own assumptions.

The following tables present the fair value hierarchy for those assets or liabilities measured at fair value on a recurring basis:

	Fair Value as of September 30, 2018
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	163	$	-	$	163


	Fair Value as of December 31, 2017
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	37	$	-	$	37

The Company uses the market approach technique to value its financial liabilities. The Company’s financial assets and liabilities carried at fair value include derivative instruments used to hedge the Company’s interest rate risks. The fair value of the Company’s interest rate swap agreements was based on LIBOR yield curves at the reporting date.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Revenues

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

17. Revenues

The following table represents a disaggregation of revenue from contracts with customers. Revenue from continuing operations originating from the following geographic areas for the three and nine months ended September 30, 2018 and 2017 consist of:

		Three Months Ended September 30, 2018
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	19,458	$	3,098	$	2,479	$	2,124	$	27,159
Service, maintenance and warranty contracts		1,077		297		79		23		1,476
Total revenues	$	20,535	$	3,395	$	2,558	$	2,147	$	28,635


		Three Months Ended September 30, 2017
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	9,758	$	3,299	$	2,675	$	2,242	$	17,974
Service, maintenance and warranty contracts		380		232		114		17		743
Total revenues	$	10,138	$	3,531	$	2,789	$	2,259	$	18,717


		Nine Months Ended September 30, 2018
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	56,153	$	10,685	$	9,485	$	6,524	$	82,847
Service, maintenance and warranty contracts		3,107		631		277		54		4,069
Total revenues	$	59,260	$	11,316	$	9,762	$	6,578	$	86,916


		Nine Months Ended September 30, 2017
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	29,901	$	10,125	$	6,886	$	6,644	$	53,556
Service, maintenance and warranty contracts		1,200		648		293		64		2,205
Total revenues	$	31,101	$	10,773	$	7,179	$	6,708	$	55,761

Refer to Note 1 for the Company’s revenue recognition policies.

Deferred revenue

As of September 30, 2018, the Company had approximately $3.3 million in deferred revenue comprised of revenue deferred from service contracts and revenue deferred from advance payments. Changes in deferred revenue from service contracts and advance payments from customers during the period were as follows:

		Nine Months Ended September 30, 2018
		(in thousands)
		Service Contracts		Customer Advances		Total
Balance, beginning of period	$	505	$	-	$	505
Addition due to business combination		848		2,128		2,976
Deferral of revenue		3,084		434		3,518
Recognition of deferred revenue		(2,933)		(793)		(3,726)
Effect of foreign currency translation		(6)		-		(6)
Balance, end of period	$	1,498	$	1,769	$	3,267

Allowance for doubtful accounts

Activity in the allowance for doubtful accounts was as follows:

		Nine Months Ended September 30, 2018
		(in thousands)

Balance, beginning of period	$	193
Addition due to business combination		102
Bad debt expense		3
Charged to allowance		(23)
Effect of foreign currency translation		26
Balance, end of period	$	301

Acquisition of DSI

As discussed in Note 4, the Company acquired DSI, a previously privately held company on January 31, 2018. The Company has adopted ASC 606 with respect to DSI as of January 31, 2018. The tables, revenue recognition policies applied, and product descriptions noted above are thus inclusive of, and reflect revenues of DSI for the periods from the acquisition date.

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2018
Income Tax [Abstract]
Income Taxes Disclosure [Text Block]	18. Income Tax Income tax from continuing operations was a benefit of approximately $0.7 million and $19 thousand for the three months ended September 30, 2018 and 2017, respectively. The effective tax rate on continuing operations was 71.8% for the three months ended September 30, 2018 compared with 2.9% for the same period in 2017. Tax benefit for the three months ended September 30, 2018 reflects a benefit determined under the annualized effective tax method. The income tax benefit for the three months ended September 30, 2017 reflects the incremental expense associated with the actual results for the three-month period as described below. Discrete items included in the tax benefit for the three months ended September 30, 2018 included foreign currency gains and losses and withholding taxes. Discrete items included in the tax benefit for the three months ended September 30, 2017 are changes to reserves for uncertain tax positions and tax impact of stock-based compensation. Income tax from continuing operations was a benefit of approximately $0.4 million and $0.1 million for the nine months ended September 30, 2018 and 2017, respectively. The effective tax rate on continuing operations was 5.2% for the nine months ended September 30, 2018 compared with 6.6% for the same period in 2017. Tax benefit for the nine months ended September 30, 2018 reflects benefit determined under the annualized effective tax method. The tax benefit for the three and nine month periods ended September 30, 2017 was based on actual results for the three and nine months periods rather than an annual effective rate estimated for the entire year. In 2017 the Company determined that using a year-to-date approach resulted in a better estimate of income tax expense/benefit based on its forecast of pre-tax income/loss, the mix of taxable income/loss across several jurisdictions with different statutory tax rates, and the impact of the full valuation allowance against U.S. deferred tax assets. The impact of recent events including U.S. tax reform and a major acquisition in January 2018 have significantly contributed to a change in the Company’s determination regarding the use of the year-to-date method, which has been discontinued effective in the first quarter of 2018, the annualized effective tax rate method is used instead. On December 22, 2017, tax reform legislation known as the Tax Cuts and Jobs Act (the Tax Act) was signed into law. For the year ended December 31, 2017, the Company recorded provisional amounts relating to the revaluation of deferred tax assets and liabilities, the impact of the mandatory repatriation of foreign earnings after electing the utilization of existing tax attributes, and for the reduction in valuation allowance on net federal deferred tax assets. In accordance with SEC guidance in Staff Accounting Bulletin No. 118, the Company is utilizing the measurement period approach for the income tax effects of tax reform for which the accounting is incomplete. Since these provisions are still based on estimates, the Company will continue to measure the impact of these areas and record any changes in subsequent quarters when information and guidance become available. As part of the 2017 Tax Act, there is a provision for the taxation of certain off-shore earnings referred to as the Global Intangible Low-Taxed Income (“GILTI”) provision. In connection with this new provision, the Company has recorded current expense within the period but continues the process of determining its final accounting policy in regard to this new tax. The difference between the Company’s effective tax rate period over period was primarily attributable to higher pre-tax income at certain individual subsidiaries in 2018 versus 2017, despite an overall pre-tax loss in both periods, as well as the impact of non-deductible acquisition costs and certain provisions of U.S. tax reform in 2018. An additional factor was the impact of changes in the valuation allowance position recorded in certain countries. For the three months ended September 30, 2018, no income tax expense or benefit was recorded for discontinued operations. In the same period in 2017, income tax expense for discontinued operations was $26 thousand. For the nine months ended September 30, 2018, an income tax benefit of $0.9 million was recorded for discontinued operations. In the same period in 2017, income tax expense for discontinued operations was $90 thousand. The Company adopted ASU 2016-09 as of January 1, 2017. As a result, the Company recorded a cumulative increase in retained earnings of $0.5 million at the beginning of the first quarter of 2017 with a corresponding increase in deferred tax assets related to the prior years’ unrecognized excess tax benefits. An equal amount of valuation allowance was also recorded against these deferred tax assets with a corresponding decrease to retained earnings resulting in a net impact of $0. In addition, vesting of restricted stock units during the nine months ended September 30, 2018 has been recognized in the current period’s income statement.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation Policies [Text Block]	Basis of Presentation The unaudited consolidated financial statements of Harvard Bioscience, Inc. and its wholly-owned subsidiaries (collectively, Harvard Bioscience or the Company) as of September 30, 2018 and for the nine months ended September 30, 2018 and 2017 have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations. The December 31, 2017 consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. However, the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which was filed with the SEC on March 16, 2018. In the opinion of management, all adjustments, which include normal recurring adjustments necessary to present a fair statement of financial position as of September 30, 2018, results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2018 and 2017 and cash flows for the nine months ended September 30, 2018 and 2017, as applicable, have been made. The results of operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the operating results for the full fiscal year or any future periods.
Reclassifications [Policy Text Block]	Reclassifications As disclosed in Note 5, on January 22, 2018, the Company sold substantially all the assets of its operating subsidiary, Denville Scientific, Inc. (Denville). The sale of Denville represented a strategic shift that has and will have a major effect on the Company’s operations and financial results. As such and pursuant to Accounting Standards Codification (ASC) 205-20 – Presentation of Financial Statements - Discontinued Operations, the operating results of Denville for the three and nine months ended September 30, 2018 and 2017 have been presented in discontinued operations in the consolidated statements of operations. Additionally, the assets and liabilities of Denville as of December 31, 2017 have been recast in the consolidated balance sheet and presented as held for sale. These reclassifications and adjustments had no effect on total amounts within the consolidated balance sheet, consolidated statements of operations and comprehensive income (loss), consolidated statements of cash flows for any of the periods presented.
Allowance for Doubtful Accounts [Policy Text Block]	Allowance for doubtful accounts The allowance for doubtful accounts reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance. The Company determines the allowance based on known troubled accounts, historical experience, and other currently available evidence.
Revenue Recognition [Policy Text Block]	Revenue recognition Nature of contracts and customers The Company’s contracts are primarily of short duration and are mostly based on the receipt and fulfilment of purchase orders. The purchase orders are binding and include pricing and all other relevant terms and conditions. The Company’s customers are primarily research scientists at universities, hospitals, government laboratories, including the United States National Institute of Health (NIH), contract research organizations, pharmaceutical and biotechnology companies. The Company also has global and regional distribution partners, and original equipment manufacturer (OEM) customers who incorporate its products into their products under their own brands. Performance obligations The Company’s performance obligations under its revenue contracts consist of its instruments, equipment, accessories, services, maintenance and extended warranties. Equipment also includes software that functions together with the tangible equipment to deliver its essential functionality. Contracts with customers may contain multiple promises such as delivery of hardware, software, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For contracts with customers that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which does not materially differ from the stated price in the contract. Instruments, equipment and accessories consist of a range of products that are used in life sciences research. Revenues from the sales of these items are recognized when transfer of control of these products to the customer occurs. Transfer of control occurs when the Company has a right to payment, and the customer has legal title to the asset and the customer or their selected carrier has possession, which is typically upon shipment. Sales on these items are therefore generally recognized at a point in time. The Company’s equipment revenue also includes the sale of wireless implantable monitors that are used for life science research purposes. The Company sells these wireless implantable monitors to pharmaceutical companies, contract research organizations and academic laboratories. In addition to sales generated from new and existing customers, these implantable devices are also sold under a program called the “exchange program”. Under this program, customers may return an implantable monitor to the Company after use, and if the returned monitor can be reprocessed and resold, they may, in exchange, purchase a replacement implantable monitor of the same model at a lower price than a new monitor. The implantable monitors that are returned by customers are reprocessed and made available for future sale. The initial sale of implantable monitors and subsequent sale of replacement implantable monitors are independent transactions. The Company has no obligation in connection with the initial sale to sell replacement implantable monitors at any future date under any fixed terms and may refuse returned implantable monitors that cannot be recovered or are obsolete. The Company has concluded that the offer to its customers that they may purchase a discounted product in the future is not a material right based on the applicable guidance within ASC 606. Service revenues consist of installation, training, data analysis, and surgeries performed on research animals. Maintenance revenue consists of post-contract support provided in relation to software that is embedded within the equipment that is sold to the customer. The Company provides standard warranties that promise the customer that the product will work as promised. These standard warranties are not a separate performance obligation. Extended warranties relate to warranties that are separately priced, and purchased in addition to a standard warranty, and are therefore a separate performance obligation. The Company has made the judgment that the customer benefits as the Company performs over the period of the contract, and therefore revenues from service, maintenance and warranty contracts are recognized over time. The Company uses the input method to recognize revenue over time, based on time elapsed, which is generally on a straight-line basis over the service period. The period over which maintenance and warranty contracts is recognized is typically one year. The period over which service revenues is recognized is generally less than one month. For sales for which transfer of control occurs upon shipment, the Company accounts for shipping and handling costs as fulfilment costs. As such, the Company records the amounts billed to the customer for shipping costs as revenue and the costs within cost of revenues upon shipment. For sales, for which control transfers to customers after shipment, the Company has elected to account for shipping and handling as activities to fulfill the promise to transfer the goods to the customer. The Company therefore accrues for the costs of shipping undelivered items in the period of shipment. Revenues expected to be recognized related to any and all remaining performance obligations are generally expected to be recognized in one year or less, as the majority of the Company's contracts have a term of less than one year. Variable Consideration The nature of the Company's contracts gives rise to certain types of variable consideration, including in limited cases volume and payment discounts. The Company analyzes sales that could include variable consideration, and estimates the expected or most likely amount of revenue after returns, trade-ins, discounts, rebates, credits, and incentives. Product returns are estimated and accrued for, based on historical information. In making these estimates, the Company considers whether the amount of variable consideration is constrained and is included in revenue only to the extent that it is probable that a significant reversal of the revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration, and its impact on the Company’s revenue recognition, was not material in any of the periods presented. The Company’s payment terms are generally from zero to sixty days from the time of invoicing, which generally occurs at the time of shipment or prior to services being performed. Payment terms vary by the type of its customers and the products or services offered. Sales taxes, value added taxes, and certain excise taxes collected from customers and remitted to governmental authorities are accounted for on a net basis, and are therefore excluded from revenues. Deferred revenue The Company records deferred revenue when cash is collected from customers prior to satisfaction of the Company’s performance obligation to the customer. Deferred revenue consists of amounts deferred related to service contracts and revenue deferred as a result of payments received in advance from customers. Deferred revenue is generally expected to be recognized within one year. The amounts included in deferred revenue from advanced payments relate to amounts that are prepaid for wireless implantable monitors under the exchange program. The Company has made the judgment that these payments do not represent a significant financing component as the customer can exercise their discretion as to when they can obtain the products that they have made a prepayment for. Advanced payments received from customers are recorded as a liability, and revenue is recognized when the Company’s performance obligations are completed. Performance obligations are completed when the product is shipped or delivered to the customer, or at the end of the exchange program if goods are not acquired prior to the termination of the contract period. Disaggregation of revenue Refer to Note 17 for revenue disaggregated by type and by geographic region as well as further information about the allowance for doubtful accounts and deferred revenue balances.

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References + Details

Accumulated Other Comprehensive Income (Tables)

9 Months Ended

Sep. 30, 2018

Accumulated Other Comprehensive Income [Abstract]

Accumulated Other Comprehensive Income [Table Text Block]

		Foreign currency		Derivatives
		translation		qualifying as		Defined benefit
(in thousands)		adjustments		hedges		pension plans		Total

Balance at December 31, 2017	$	(9,755)	$	37	$	(958)	$	(10,676)

Other comprehensive income before reclassifications		(1,037)		27		-		(1,010)
Amounts reclassified from AOCI		-		99		-		99

Other comprehensive income		(1,037)		126		-		(911)

Balance at September 30, 2018	$	(10,792)	$	163	$	(958)	$	(11,587)

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2018

Acquisition Disclosure [Abstract]

Schedule of Business Acquisitions [Table Text Block]

		(in thousands)
Tangible assets	$	32,525
Liabilities assumed		(11,587)
Net assets		20,938

Goodwill and intangible assets:
Goodwill		19,348
Amortizable intangible assets:
Trade name		3,524
Developed technology		25,570
Customer relationships		9,837
In-process research and development		1,387
Total amortizable intangible assets		40,318
Deferred tax liabilities, net		(10,020)
Total goodwill and intangible assets, net of tax		49,646
Acquisition purchase price	$	70,584


Tangible assets and liabilities assumed, as referenced above, preliminarily consist of the following:

Cash acquired	$	2,576
Accounts receivable, net		5,069
Inventories		11,512
Other current assets		809
Property, plant and equipment, net		2,090
Deferred income tax assets, net		10,469
Tangible assets	$	32,525

Accounts payable and accrued liabilities	$	5,639
Deferred revenue including customer advances		2,976
Other long term liabilities		2,972
Liabilities assumed	$	11,587

Business Acquisition, Pro Forma Information [Table Text Block]

		Three Months Ended September 30,				Nine Months Ended September 30,
		Three Months Ended September 30,				Nine Months Ended September 30,
		2018		2017		2018		2017
		(in thousands)
Pro Forma
Revenues	$	28,713	$	27,997	$	90,384	$	88,547
Income (loss) from continuing operations		155		(1,845)		(236)		(9,719)

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2018

Discontinued Operations [Abstract]

Disposal Groups, Including Discontinued Operations, Assets and Liabilities Held For Sale [Table Text Block]


			December 31,
			2017
		(in thousands)
Carrying amounts of major classes of assets
	Cash	$	541
	Accounts receivable, net		2,854
	Inventories		4,505
	Other receivables and other assets		504
	Current assets held for sale		8,404

	Property, plant and equipment		397
	Amortizable intangible assets		5,930
	Allocation of goodwill		3,633
	Long term assets held for sale		9,960
Total assets of the disposal group classified as held for sale in the consolidated balance sheet		$	18,364

Carrying amounts of major classes of liabilities
	Accounts payable and accrued expenses	$	1,736
	Other current liabilities		121
	Current liabilities held for sale		1,857

	Deferred income tax liabilities		1,311
	Long term liabilities held for sale		1,311
Total liabilities of the disposal group classified as held for sale in the consolidated balance sheet		$	3,168

Disposal Groups, Including Discontinued Operations,Income Loss [Table Text Blcok]

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018			2017	2018			2017
	(in thousands)				(in thousands)
Revenues	$	-	$	6,333	$	893	$	18,658
Cost of revenues		-		(4,194)		(534)		(12,383)
Operating and other expenses		-		(1,885)		(673)		(6,044)
Gain on disposal of discontinued operations		-		-		1,251		-
Income from discontinued operations before income taxes	$	-	$	254	$	937	$	231
Income tax expense (benefit)		-		26		(883)		90
Income from discontinued operations		-		228		1,820		141

Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2018

Goodwill And Other Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets and Goodwill [Table Text Block]

									Weighted
									Average
		September 30, 2018				December 31, 2017			Life	(a)
		(in thousands)
Amortizable intangible assets:		Gross		Accumulated Amortization		Gross		Accumulated Amortization
Existing technology	$	41,536	$	(15,516)	$	16,173	$	(13,179)	7.3	Years
Trade names		7,882		(2,718)		4,443		(2,280)	7.9	Years
Distribution agreements/customer relationships		22,808		(9,240)		13,197		(8,373)	10.8	Years
In-process research and development		1,387		(47)		-		-	7.2	Years
Patents		218		(200)		223		(174)	0.4	Years
Total amortizable intangible assets		73,831	$	(27,721)		34,036	$	(24,006)

Indefinite-lived intangible assets:
Goodwill		55,801				36,336
Other indefinite-lived intangible assets		1,238				1,244
Total goodwill and other indefinite-lived intangible assets		57,039				37,580

Total intangible assets, gross	$	130,870			$	71,616

(a) Weighted average life as of September 30, 2018.

Goodwill Rollforward [Table Text Block]

			(in thousands)
Balance at December 31, 2017		$	36,336
	Goodwill arising from business combination		19,348
	Effect of change in currency translation		117
Balance at September 30, 2018		$	55,801

Inventories (Tables)

9 Months Ended

Sep. 30, 2018

Inventories Disclosure [Abstract]

Schedule of Inventory [Table Text Block]

			September 30,		December 31,
			2018		2017
			(in thousands)
Finished goods		$	7,569	$	5,779
Work in process			3,849		1,042
Raw materials			14,321		10,027
	Total	$	25,739	$	16,848

Property, Plant and Equipment (Tables)

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment Disclosure [Abstract]

Schedule Of Property Plant And Equipment [Table Text Block]

		September 30,		December 31,
		2018		2017
		(in thousands)
Land, buildings and leasehold improvements	$	2,478	$	2,197
Machinery and equipment		8,711		7,022
Computer equipment and software		9,519		8,819
Furniture and fixtures		1,789		1,139
Automobiles		117		120
		22,614		19,297
Less: accumulated depreciation		(17,222)		(15,554)
Property, plant and equipment, net	$	5,392	$	3,743

Warranties (Tables)

9 Months Ended

Sep. 30, 2018

Warranties Disclosure [Abstract]

Warranty Rollforward Disclosure [Table Text Block]

		Beginning	(Payments)\			Ending
		Balance	Credits	Additions		Balance
		(in thousands)

Year ended December 31, 2017	$	193	(7)	60	$	246

Nine months ended September 30, 2018	$	246	5	140	$	391

Employee Benefit Plans (Tables)

9 Months Ended

Sep. 30, 2018

Employee Benefit Plans Disclosure [Abstract]

Schedule of Changes in Projected Benefit Obligations [Table Text Block]

		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2018		2017		2018		2017
		(in thousands)
Components of net periodic benefit cost:
Interest cost	$	121	$	141	$	371	$	399
Expected return on plan assets		(187)		(179)		(575)		(505)
Net amortization loss		53		98		163		276
Curtailment gain		(41)		-		(41)		-
Net periodic benefit (income) cost	$	(54)	$	60	$	(82)	$	170

Leases (Tables)

9 Months Ended

Sep. 30, 2018

Leases Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

		Operating
		Leases
		(in thousands)
2019	$	3,217
2020		2,317
2021		1,130
2022		1,091
2023		1,093
Thereafter		772
Net minimum lease payments	$	9,620

Capital Stock (Tables)

9 Months Ended

Sep. 30, 2018

Capital Stock Disclosure [Abstract]

Schedule Of Stock Options And Restricted Stock Units Activity Rollforward [Table Text Block]

		Stock Options			Restricted Stock Units			Market Condition RSU's
				Weighted
		Stock		Average	Restricted			Market
		Options		Exercise	Stock Units		Grant Date	Condition RSU's		Grant Date
		Outstanding		Price	Outstanding		Fair Value	Outstanding		Fair Value

Balance at December 31, 2017		3,780,244	$	3.95	1,796,927	$	2.69	164,127	$	4.81
	Granted	50,000		4.84	608,189		4.34	156,944		4.19
	Exercised	(1,689,755)		3.50	-		-	-		-
	Vested (RSUs)	-		-	(824,843)		2.87	(69,667)		4.81
	Cancelled / forfeited	(204,391)		4.96	(346,462)		2.82	(134,460)		4.63
Balance at September 30, 2018		1,936,098	$	4.26	1,233,811	$	3.35	116,944	$	4.19

Stock Based Compensation Expense Activity By Function [Table Text Block]

		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2018		2017		2018		2017
		(in thousands)

Cost of revenues	$	19	$	16	$	45	$	45
Sales and marketing		105		150		331		395
General and administrative		308		706		1,581		1,989
Research and development		54		36		125		102
Discontinued operations		-		25		150		73
Total stock-based compensation	$	486	$	933	$	2,232	$	2,604

Basic and Diluted Shares [Table Text Block]

	Three Months Ended		Nine Months Ended
	September 30,		September 30,
	2018	2017	2018	2017

Basic	36,947,052	34,840,324	36,169,536	34,705,947
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSUs	-	-	-	-
Diluted	36,947,052	34,840,324	36,169,536	34,705,947

Black-Scholes option pricing model [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]

Table Of Assumptions [Table Text Block]

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Volatility	43.38	%	41.99	%	42.63	%	41.30	%
Risk-free interest rate	2.78	%	1.74	%	2.81	%	1.88	%
Expected holding period (in years)	4.77	years	5.10	years	4.90	years	5.16	years
Dividend yield	-	%	-	%	-	%	-	%

Monte-Carlo valuation simulation [Member]

Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]

Table Of Assumptions [Table Text Block]

	Nine Months Ended
	September 30,
	2018
Volatility	44.02	%
Risk-free interest rate	2.27	%
Correlation coefficient	0.07	%
Dividend yield	-	%

Long Term Debt (Tables)

9 Months Ended

Sep. 30, 2018

Long Term Debt Disclosure [Abstract]

Schedule of Debt [Table Text Block]

		September 30,		December 31,
		2018		2017
		(in thousands)
Long-term debt:
Term loan	$	62,752	$	11,899
Total unamortized deferred financing costs		(1,706)		(151)
Total debt		61,046		11,748
Less: current installments		(2,200)		(2,800)
Current unamortized deferred financing costs		401		35
Long-term debt	$	59,247	$	8,983

Derivative (Tables)

9 Months Ended

Sep. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]


				September 30, 2018		September 30, 2018
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	34,663	$	163


				December 31, 2017		December 31, 2017
				Notional Amount		Fair Value (a)
Derivatives designated as hedging instruments under ASC 815		Balance sheet classification		(in thousands)
Interest rate swaps		Other assets (long term liabilities)	$	11,900	$	37

	(a) See Note 16 for the fair value measurements related to these financial instruments.

Schedule of Cash Flow Hedges Included in AOCI [Table Text Block]

Derivatives in Hedging Relationships	Amount of gain (loss) recognized in OCI on derivative (effective portion)
	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
	(in thousands)
Interest rate swaps	$	126	$	-	$	27	$	(89)

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]

Details about AOCI Components	Amount reclassified from AOCI into income (effective portion)
	Three Months Ended September 30,				Nine Months Ended September 30,				Location of amount reclassified from AOCI
	2018		2017		2018		2017		into income (effective portion)
	(in thousands)
Interest rate swaps	$	55	$	21	$	99	$	43	Interest expense

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2018

Fair Value Disclosures [Abstract]

Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis [Table Text Block]

	Fair Value as of September 30, 2018
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	163	$	-	$	163


	Fair Value as of December 31, 2017
(In thousands)		Level 1		Level 2		Level 3		Total
Assets (Liabilities):
Interest rate swap agreements	$	-	$	37	$	-	$	37

Revenues (Tables)

9 Months Ended

Sep. 30, 2018

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue [Table Text Block]

		Three Months Ended September 30, 2018
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	19,458	$	3,098	$	2,479	$	2,124	$	27,159
Service, maintenance and warranty contracts		1,077		297		79		23		1,476
Total revenues	$	20,535	$	3,395	$	2,558	$	2,147	$	28,635


		Three Months Ended September 30, 2017
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	9,758	$	3,299	$	2,675	$	2,242	$	17,974
Service, maintenance and warranty contracts		380		232		114		17		743
Total revenues	$	10,138	$	3,531	$	2,789	$	2,259	$	18,717


		Nine Months Ended September 30, 2018
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	56,153	$	10,685	$	9,485	$	6,524	$	82,847
Service, maintenance and warranty contracts		3,107		631		277		54		4,069
Total revenues	$	59,260	$	11,316	$	9,762	$	6,578	$	86,916


		Nine Months Ended September 30, 2017
		(in thousands)
		United States		United Kingdom		Germany		Rest of the world		Total
Instruments, equipment and accessories	$	29,901	$	10,125	$	6,886	$	6,644	$	53,556
Service, maintenance and warranty contracts		1,200		648		293		64		2,205
Total revenues	$	31,101	$	10,773	$	7,179	$	6,708	$	55,761

Activity in allowance for doubtful accounts [Table Text Block]

		Nine Months Ended September 30, 2018
		(in thousands)

Balance, beginning of period	$	193
Addition due to business combination		102
Bad debt expense		3
Charged to allowance		(23)
Effect of foreign currency translation		26
Balance, end of period	$	301

Service Contracts [Member]

Deferred Revenue Arrangement [Line Items]

Deferred Revenue, by Arrangement, Disclosure [Table Text Block]

		Nine Months Ended September 30, 2018
		(in thousands)
		Service Contracts		Customer Advances		Total
Balance, beginning of period	$	505	$	-	$	505
Addition due to business combination		848		2,128		2,976
Deferral of revenue		3,084		434		3,518
Recognition of deferred revenue		(2,933)		(793)		(3,726)
Effect of foreign currency translation		(6)		-		(6)
Balance, end of period	$	1,498	$	1,769	$	3,267

Recently Issued Accounting Pronouncements (Details)	9 Months Ended
Recently Issued Accounting Pronouncements (Details)	Sep. 30, 2018
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	The Company has not yet concluded on the impact of the adoption on its consolidated financial position, results of operations and cash flows; however, the Company expects that the new standard will have a material effect on its consolidated balance sheet related to the recognition of new assets and lease liabilities.
Accounting Standards Update 2017-12 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	The Company is evaluating the requirements of this guidance and has not yet determined the impact of the adoption on its consolidated financial position, results of operations and cash flows.
Accounting Standards Update 2014-09 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	The timing of recognizing revenues for these revenue streams did not materially change. Additionally, the adoption of ASU 2014-09 did not have a material impact on the Company’s financial position, results of operations, equity or cash flows as of the adoption date or for the three months ended March 31, 2018.
Accounting Standards Update 2017-09 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
New Accounting Pronouncement or Change in Accounting Principle, Description	The Company adopted this guidance on January 1, 2018, and the new standard did not have a material impact on its consolidated financial position, results of operations and cash flows.

- Definition

Disclosure related to a new accounting pronouncement or a change in accounting principle, including the nature and reason for the change and the effect of the change on prior periods and the current period.

+ References + Details

Accumulated Other Comprehensive Income (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	$ (10,676)
Other Comprehensive Income (Loss) before Reclassifications	(1,010)
Amounts reclassified from AOCI	99
Other Comprehensive Income (Loss), Net of Tax, total	(911)
Closing Balance	(11,587)
Foreign currency translation adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(9,755)
Other Comprehensive Income (Loss) before Reclassifications	(1,037)
Amounts reclassified from AOCI	0
Other Comprehensive Income (Loss), Net of Tax, total	(1,037)
Closing Balance	(10,792)
Derivatives qualifying as hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	37
Other Comprehensive Income (Loss) before Reclassifications	27
Amounts reclassified from AOCI	99
Other Comprehensive Income (Loss), Net of Tax, total	126
Closing Balance	163
Defined benefit pension plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Opening Balance	(958)
Other Comprehensive Income (Loss) before Reclassifications	0
Amounts reclassified from AOCI	0
Other Comprehensive Income (Loss), Net of Tax, total	0
Closing Balance	$ (958)

Acquisitions (Narratives) (Details) - USD ($) $ in Thousands		3 Months Ended	8 Months Ended	9 Months Ended
	Jan. 31, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Business Acquisition, Effective Date of Acquisition				Jan. 31, 2018
Acquisition purchase price	$ 70,600
Business Acquisition, Description of Acquired Entity				DSI, a St. Paul, Minnesota-based life science research company, is a recognized leader in physiologic monitoring focused on delivering preclinical products, systems, services and solutions to its customers.
Business Acquisition Direct Acquisition Costs In Income Statement			$ 3,000	$ 3,000	$ 0
The results of operations for DSI:
Revenue of Acquiree since Acquisition Date			29,300
Earnings or Loss of Acquiree since Acquisition Date			31
Busniess combination purchase accounting inventory fair value step up amortization			3,800
Preliminary amount of inventory fair value step up			3,800	$ 3,800
Amortization Period of purchase accounting inventory fair value step up amortization				5 months 15 days
Intangible asset amortization expense			$ 2,900
Provisional Information, Initial Accounting Incomplete, Adjustments [Abstract]
Purchase price adjustments, decrease to other long term liabilities		$ (1,600)
Purchase price adjustments, increase to deferred tax liabilities		1,400
Purchase price adjustments, increase in net working capital		600
Goodwill Purchase Accounting Adjustments		$ 600
Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 4 months
Trade Names [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 11 months
Trade Names [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				9 years 5 months
Developed Technology [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 4 months
Developed Technology [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				8 years 2 months
Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				10 years 10 months
Customer Relationships [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				12 years 5 months
In-process research and development [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 2 months
In-process research and development [Member] \| Data Sciences International, Inc. (DSI) [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Assets, Weighted Average Useful Life				7 years 5 months

Acquisitions (Details 1) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Acquisitions (Details 1) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 31, 2018	Dec. 31, 2017
Goodwill and intangible assets
Goodwill	$ 55,801		$ 55,801			$ 36,336
Data Sciences International, Inc. (DSI) [Member]
Recognized Identifiable Assets Acquired and Liabilities Assumed [Abstract]
Tangible assets					$ 32,525
Liabilities assumed					(11,587)
Net assets					20,938
Goodwill and intangible assets
Goodwill					19,348
Amortizable intangible assets					40,318
Deferred tax, net					(10,020)
Total goodwill and intangible assets, net of tax					49,646
Acquisition purchase price					70,584
Tangible assets and liabilities assumed, as referenced above, preliminarily consist of the following:
Cash acquired					2,576
Accounts receivable, net					5,069
Inventories					11,512
Other current assets					809
Property, plant and equipment, net					2,090
Deferred income tax assets, net					10,469
Tangible assets					32,525
Accounts payable and accrued liabilities					5,639
Deferred revenue including customer advances					2,976
Other long term liabilities					2,972
Liabilities assumed					11,587
Business Acquisitions Pro Forma Revenue	28,713	$ 27,997	90,384	$ 88,547
Business Acquisitions Pro Forma Net Income Loss	$ 155	$ (1,845)	$ (236)	$ (9,719)
Trade Names [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets					3,524
Developed Technology [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets					25,570
Customer Relationships [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets					9,837
In-process research and development [Member] \| Data Sciences International, Inc. (DSI) [Member]
Goodwill and intangible assets
Amortizable intangible assets					$ 1,387

Discontinued Operations (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Jan. 22, 2018
Discontinued Operations [Abstract]
Discontinued Operation, Name	Denville
Sale price of of assets Denville				$ 20,000
Earn out provision of discontinued operations				3,000
Proceeds From Divestiture Of Business		$ 15,754	$ 0
Contingent Consideration, Earn-out				$ 3,000
Earn out performance metrics period		2 years
Amortization of Intangible Assets		$ 4,030	1,825
Denville wholly owned subidiary, discontinued operations [member]
Amortization of Intangible Assets		$ 47	$ 700

Discontinued Operations - Assets and Liabilities held for sale (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Carrying amounts of major classes of assets
Cash		$ 541
Accounts receivable, net		2,854
Inventories		4,505
Other receivables and other assets		504
Current assets held for sale	$ 0	8,404
Property, plant and equipment		397
Amortizable intangible assets		5,930
Allocation of goodwill		3,633
Long term assets held for sale	0	9,960
Total assets of the disposal group classified as held for sale in the consolidated balance sheet		18,364
Carrying amounts of major classes of liabilities
Accounts payable and accrued expenses		1,736
Other current liabilities		121
Current liabilities held for sale	0	1,857
Deferred income tax liabilities		1,311
Long term liabilities held for sale	$ 0	1,311
Total liabilities of the disposal group classified as held for sale in the consolidated balance sheet		$ 3,168

Discontinued Operations - income (loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Discontinued Operation, Income Statement Disclosures [Abstract]
Revenues	$ 0	$ 6,333	$ 893	$ 18,658
Cost of revenues	0	(4,194)	(534)	(12,383)
Operating and other expenses	0	(1,885)	(673)	(6,044)
Gain on disposal of discontinued operations	0	0	1,251	0
Income (loss) from discontinued operations before income taxes	0	254	937	231
Income tax (benefit) expense	0	26	(883)	90
Income (loss) from discontinued operations	$ 0	$ 228	$ 1,820	$ 141

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

Goodwill and Other Intangible Assets (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Goodwill And Other Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 1,468	$ 400	$ 3,983	$ 1,158
Estimated Amortization Expense Next Twelve Months	5,600		5,600
Estimated Amortization Expense Year 2	5,800		5,800
Estimated Amortization Expense Year 3	5,800		5,800
Estimated Amortization Expense Year 4	5,700		5,700
Estimated Amortization Expense Year 5	$ 5,700		$ 5,700

Goodwill and Other Intangible Assets (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 73,831	$ 34,036
Finite-Lived Intangible Assets, Accumulated Amortization	(27,721)	(24,006)
Goodwill	55,801	36,336
Other indefinite lived intangible assets	1,238	1,244
Total goodwill and other indefinite lived intangible assets	57,039	37,580
Total intangible assets	130,870	71,616
Existing technology [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	41,536	16,173
Finite-Lived Intangible Assets, Accumulated Amortization	$ (15,516)	(13,179)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 4 months
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 7,882	4,443
Finite-Lived Intangible Assets, Accumulated Amortization	$ (2,718)	(2,280)
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 11 months
Distribution agreements/customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 22,808	13,197
Finite-Lived Intangible Assets, Accumulated Amortization	$ (9,240)	(8,373)
Finite-Lived Intangible Assets, Weighted Average Useful Life	10 years 10 months
In-process research and development [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 1,387	0
Finite-Lived Intangible Assets, Accumulated Amortization	$ (47)	0
Finite-Lived Intangible Assets, Weighted Average Useful Life	7 years 2 months
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 218	223
Finite-Lived Intangible Assets, Accumulated Amortization	$ (200)	$ (174)
Finite-Lived Intangible Assets, Weighted Average Useful Life	5 months

Goodwill and Other Intangible Assets (Details 2) $ in Thousands	9 Months Ended
	Sep. 30, 2018 USD ($)
Goodwill And Other Intangible Assets Disclosure [Abstract]
Goodwill, Beginning Balance	$ 36,336
Goodwill arising through business combination	19,348
Effect of change in currency translation	117
Goodwill, Ending Balance	$ 55,801

Inventories (Details 1) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventories Disclosure [Abstract]
Finished Goods	$ 7,569	$ 5,779
Work in Process	3,849	1,042
Raw Materials	14,321	10,027
Total Inventories, Net	$ 25,739	$ 16,848

Property, Plant and Equipment (Details 1) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 22,614	$ 19,297
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(17,222)	(15,554)
Property, plant and equipment, net	5,392	3,743
Land, buildings and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	2,478	2,197
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	8,711	7,022
Computer equipment and software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	9,519	8,819
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,789	1,139
Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 117	$ 120

Related Party Transactions (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 900	$ 500	$ 2,600	$ 1,300
Multi Channel Systems MCS GmbH [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	77	64	200	200
Triangle BioSystems, Inc. [Member]
Business Acquisition [Line Items]
Operating Leases, Rent Expense, Net	$ 10	$ 11	$ 32	$ 32

Warranties (Details 1) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Warranties (Details 1) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Product Warranty Disclosure [Abstract]
Warranty, Beginning Balance	$ 246	$ 193
Warranty (payments) or credits	5	(7)
Warranty additions	140	60
Warranty, Ending Balance	$ 391	$ 246

Employee Benefit Plans (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Employee Benefit Plans Disclosure [Abstract]
Expected employer contribution in current remaining fiscal year	$ 0.2		$ 0.2
Defined Benefit Plan Payments In Current Fiscal Year	0.2	$ 0.2	0.5	$ 0.5
Defined Benefit Plans Liabilities Noncurrent	$ 1.2		$ 1.2		$ 1.2

Employee Benefit Plans (Details 1) - USD ($)	3 Months Ended		9 Months Ended
Employee Benefit Plans (Details 1) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employee Benefit Plans Disclosure [Abstract]
Interest Cost	$ 121,000	$ 141,000	$ 371,000	$ 399,000
Expected Return on Plan Assets	(187,000)	(179,000)	(575,000)	(505,000)
Net Amortization Loss	53,000	98,000	163,000	276,000
Curtailment Gain	(41,000)	0	(41,000)	0
Net Periodic Benefit Cost, Total	$ (54,000)	$ 60,000	$ (82,000)	$ 170,000

Leases (Narratives) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
Leases (Narratives) (Details) - USD ($) $ in Millions	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2018
Leases Disclosure [Abstract]
Estimated Rental Expenses Current Year					$ 3.4
Operating Leases, Rent Expense, Net	$ 0.9	$ 0.5	$ 2.6	$ 1.3
Lease Expiration Date	Dec. 31, 2023

Leases (Details 1) $ in Thousands	Sep. 30, 2018 USD ($)
Leases Disclosure [Abstract]
2019	$ 3,217
2020	2,317
2021	1,130
2022	1,091
2023	1,093
Thereafter	772
Operating Leases, Total Future Minimum Payments Due	$ 9,620

Capital Stock (Narratives) (Details) - USD ($) $ / shares in Units, $ in Millions		3 Months Ended			9 Months Ended
	Aug. 03, 2018	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Apr. 02, 2018	Feb. 06, 2018	Dec. 31, 2017	May 18, 2017
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Preferred stock purchase right terms					The Shareholder Rights Plan expired, with no rights having become exercisable, in accordance with its terms on the close of business on February 6, 2018.
Preferred stock issued or outstanding		0			0
Preferred stock purchase right option exercised								0
Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date					85.00%
Employee Stock Purchase Plan Shares Authorized										1,050,000
Stock issued during the year, Shares, Employee Stock Purchase Plans					24,907	39,602
Total amount of common stock issued under ESOP		826,361			826,361
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							20,908,929
Increase In Number Of Shares Authorized For Issuance Under Stock Option And Incentive Plan							3,400,000			300,000
Target number of these restricted stock units					608,189
Deferred Compensation Arrangement with Individual, Maximum Contractual Term					10 years
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		3,286,853	5,789,838		3,286,853	5,789,838
Weighted Average Estimated Black Scholes Value Of Option Grants		$ 2.34	$ 1.24		$ 1.97	$ 1.17
Preferred Stock - Shares Authorized		5,000,000			5,000,000				5,000,000
Cumulative effect adjustment to retained earnings				$ 0.1
Maximum percentage of target number of restricted stock units					150.00%
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Target number of these restricted stock units					156,944
Deferred stock awards of Market Condition RSU, Approved Aug 2015 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Number of shares vested	69,667
Deferred stock awards of Market Condition RSU, Approved May 2018 [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Target number of these restricted stock units					116,944
Maximum percentage of target number of restricted stock units					150.00%
Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 4.19
Minimum [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					1 year
Maximum [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					4 years

Capital Stock (Details 1)	9 Months Ended
Capital Stock (Details 1)	Sep. 30, 2018 $ / shares shares
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Opening Balance Stock Options Outstanding \| shares	3,780,244
Options, Grants in Period, Gross \| shares	50,000
Stock option exercises during the year, Shares \| shares	(1,689,755)
Options, Forfeitures and Expirations in Period \| shares	(204,391)
Closing Balance Stock Options Outstanding \| shares	1,936,098
Begining Balance Weighted Average Exercise Price \| $ / shares	$ 3.95
Options, Grants in Period, Weighted Average Exercise Price \| $ / shares	4.84
Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price \| $ / shares	4.96
Options, Exercises in Period, Weighted Average Exercise Price \| $ / shares	3.5
Closing Balance Weighted Average Exercise Price \| $ / shares	$ 4.26
Begining Balance Restricted Stock Units Outstanding \| shares	1,796,927
Restricted stock units, Grants in Period \| shares	608,189
Retricted Stock Units, Vested in Period \| shares	(824,843)
Restricted Stock Units, cancelled/ forfeited \| shares	(346,462)
Closing Balance Restricted Stock Units Outstanding \| shares	1,233,811
Begining Balance Grant Date Fair Value Of Restricted Stock Units \| $ / shares	$ 2.69
Granted, Restricted Stock Units Grant Date Fair Value \| $ / shares	4.34
Vested in period, Restricted Stock Unit, Fair Value \| $ / shares	2.87
Forfeited in Period, Restricted Stock Unit Grant Date Fair Value \| $ / shares	2.82
Closing Balance Grant Date Fair Value Of Restricted Stock Units \| $ / shares	$ 3.35
Market Condition Restricted Stock Unit [Member]
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]
Begining Balance Restricted Stock Units Outstanding \| shares	164,127
Restricted stock units, Grants in Period \| shares	156,944
Retricted Stock Units, Vested in Period \| shares	(69,667)
Restricted Stock Units, cancelled/ forfeited \| shares	(134,460)
Closing Balance Restricted Stock Units Outstanding \| shares	116,944
Begining Balance Grant Date Fair Value Of Restricted Stock Units \| $ / shares	$ 4.81
Granted, Restricted Stock Units Grant Date Fair Value \| $ / shares	4.19
Vested in period, Restricted Stock Unit, Fair Value \| $ / shares	4.81
Forfeited in Period, Restricted Stock Unit Grant Date Fair Value \| $ / shares	4.63
Closing Balance Grant Date Fair Value Of Restricted Stock Units \| $ / shares	$ 4.19

Capital Stock - Assumptions Black Scholes and Monte Carlo (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Black-Scholes option pricing model [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	43.38%	41.99%	42.63%	41.30%
Risk-free interest rate	2.78%	1.74%	2.81%	1.88%
Expected holding period (in years)	4 years 10 months	5 years	4 years 11 months	5 years 2 months
Dividend yield	0.00%	0.00%	0.00%	0.00%
Monte-Carlo valuation simulation [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Volatility	44.02%
Risk-free interest rate	2.27%
Correlation coefficient	0.07%
Dividend yield	0.00%

Capital Stock - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 486	$ 933	$ 2,232	$ 2,604
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	19	16	45	45
Selling and Marketing Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	105	150	331	395
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	308	706	1,581	1,989
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	54	36	125	102
Discontinued Operations [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based Compensation	$ 0	$ 25	$ 150	$ 73

Capital Stock - Weighted average number of shares (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Weighted Average Number Diluted Shares Outstanding Adjustment [Abstract]
Basic	36,947,052	34,840,324	36,169,536	34,705,947
Effect of assumed conversion of employee and director stock options, restricted stock units and Market Condition RSU's	0	0	0	0
Diluted	36,947,052	34,840,324	36,169,536	34,705,947

Long Term Debt (Narratives) (Details) - USD ($) $ in Thousands		9 Months Ended
	Jan. 31, 2018	Sep. 30, 2018	Jan. 22, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Secured Debt		$ 61,046		$ 11,748
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000
Maturity of debt instrument in years and months		5 years
Debt Instrument, Payment Terms	the outstanding term loans amortize in equal quarterly installments equal to $0.4 million per quarter on such date and during each of the next three quarters thereafter, $0.6 million per quarter during the next four quarters thereafter and $0.8 million per quarter thereafter, with a balloon payment at maturity.
Debt Instrument Quarterly Payment Current Year	$ 400
Debt Instrument Quarterly Payment Next Year	600
Debt Instrument Quarterly Payment Thereafter	800
Limitation on pledges of capital stock of foreign subsidiaries		65.00%
Line of Credit Facility, Amount Outstanding			$ 11,900
Line of Credit Facility, Remaining Borrowing Capacity		$ 8,500
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	25,000
Line of Credit Facility, Amount Outstanding	$ 4,800
Interest Rate As Of Reporting Date	8.34%
Revolving Credit Facility [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	a base rate plus 4.75%
Basis Spread on Variable Rate	4.75%
Floor Interest Rate	4.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Description Of Variable Rate Basis	London Interbank Offered Rate (LIBOR) rate plus 6.25%
Basis Spread on Variable Rate	6.25%
Floor Interest Rate	1.25%
Term Loan [Member]
Debt Instrument [Line Items]
Secured Debt		$ 64,000
Interest Rate As Of Reporting Date	8.76%

Long Term Debt (Details 1) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument
Term Loan	$ 62,752	$ 11,899
DDTL	0	0
Revolving Credit Facility	0	0
Total unamortized deferred financing costs	(1,706)	(151)
Total Debt	61,046	11,748
Less: current installments	(2,200)	(2,800)
Current unamortized deferred financing costs	401	35
Long-term debt	$ 59,247	$ 8,983

Derivative (Narratives) (Details) - USD ($)		9 Months Ended
Derivative (Narratives) (Details) - USD ($)	Jan. 31, 2018	Sep. 30, 2018	Dec. 31, 2017
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Deferred losses on derivative instruments accumulated in AOCI expected to be reclassified to earnings		$ 54,000
Derivative Interest Rate Swap Effective Percentage		100.00%
Secured Debt		$ 61,046,000	$ 11,748,000
Line of Credit Facility, Maximum Borrowing Capacity	$ 25,000,000
Proceeds from interest rate swaps unwinding		100,000
Other liabilities-non current [Member] \| Derivatives qualifying as hedges [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Derivatives		$ 34,663,000	$ 11,900,000
Term Loan [Member]
Derivative Instruments And Hedging Activities Disclosure [Line Items]
Notional Amount of Interest Rate Swaps	$ 36,000,000
LIBOR Fixed Rate	2.72%
Secured Debt	$ 64,000,000

Derivative (Details 1) - Other liabilities-non current [Member] - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Derivatives, Fair Value [Line Items]
Notional Amount of Interest Rate Derivatives	$ 34,663	$ 11,900
Derivative Liability, Fair Value, Net	$ 163	$ 37

Derivative (Details 2) - Derivatives qualifying as hedges [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ 126,000	$ 0	$ 27,000	$ (89,000)
Interest Expense [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion	$ 55,000	$ 21,000	$ 99,000	$ 43,000

Fair Value Measurements (Details) - Derivatives qualifying as hedges [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 163	$ 37
Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	163	37
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Derivative Liabilities	$ 0	$ 0

Revenues - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 28,635	$ 18,717	$ 86,916	$ 55,761
Instruments, equipment and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	27,159	17,974	82,847	53,556
Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,476	743	4,069	2,205
Segment, Geographical, United States [Member]
Disaggregation of Revenue [Line Items]
Revenues	20,535	10,138	59,260	31,101
Segment, Geographical, United States [Member] \| Instruments, equipment and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	19,458	9,758	56,153	29,901
Segment, Geographical, United States [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	1,077	380	3,107	1,200
Segment, Geographical, United Kingdom [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,395	3,531	11,316	10,773
Segment, Geographical, United Kingdom [Member] \| Instruments, equipment and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	3,098	3,299	10,685	10,125
Segment, Geographical, United Kingdom [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	297	232	631	648
Segment, Geographical, Germany [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,558	2,789	9,762	7,179
Segment, Geographical, Germany [Member] \| Instruments, equipment and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,479	2,675	9,485	6,886
Segment, Geographical, Germany [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	79	114	277	293
Rest Of The World [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,147	2,259	6,578	6,708
Rest Of The World [Member] \| Instruments, equipment and accessories [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,124	2,242	6,524	6,644
Rest Of The World [Member] \| Service, maintenance and warranty contracts [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 23	$ 17	$ 54	$ 64

Revenues - Deferred revenue (Details) $ in Thousands	9 Months Ended
Revenues - Deferred revenue (Details) $ in Thousands	Sep. 30, 2018 USD ($)
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	$ 505
Addition due to business combination	2,976
Deferral of revenue	3,518
Recognition of deferred revenue	(3,726)
Effect of foreign currency translation	(6)
Deferred Revenue, ending balance	3,267
Service Contracts [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	505
Addition due to business combination	848
Deferral of revenue	3,084
Recognition of deferred revenue	(2,933)
Effect of foreign currency translation	(6)
Deferred Revenue, ending balance	1,498
Customer Advances [Member]
Movement in Deferred Revenue [Roll Forward]
Deferred Revenue, beginning balance	0
Addition due to business combination	2,128
Deferral of revenue	434
Recognition of deferred revenue	(793)
Effect of foreign currency translation	0
Deferred Revenue, ending balance	$ 1,769

Revenues - Allowance for doubtful debts (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
AllowanceForDoubtfulAccountsReceivableRollforward
Balance, beginning of period	$ 193
Addition due to business combination	102
Provision for allowance for doubtful accounts	3	$ 1
Charged to allowance	(23)
Other	26
Balance, end of period	$ 301

Income Tax (Narratives) (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
Income Tax (Narratives) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax [Abstract]
Effective Income Tax Rate	71.80%	2.90%		5.20%	6.60%
Income tax expense (benefit)	$ (652)	$ (19)		$ (416)	$ (141)
Discontinued Operation, Tax Effect of Discontinued Operation	$ 0	$ 26		$ (883)	$ 90
New Accounting Pronouncements Or Change In Accounting Principle
Cumulative effect adjustment to retained earnings			$ 100
ASU 2016-09
New Accounting Pronouncements Or Change In Accounting Principle
Valuation allowance recorded against the deferred tax assets			0
Cumulative effect adjustment to retained earnings			$ 500

- Definition

+ References + Details